Futurescapes: Expectations in Europe for relative effectiveness evidence for drugs in 2020

Journal of Comparative Effectiveness Research

Volumn 4, Issue 4, 2015, Pages 401-418

  Towse, Adrian ^a   Garau, Martina ^a   Mohr, Penny ^b   Messner, Donna A ^c  

^a Southside   (United Kingdom)

^b Outcomes Research Institute   (United States)

^c Center for Medical Technology Policy   (United States)

Author keywords

adaptive licensing; coverage with evidence development; drug development; electronic health records; HTA methods; performance based risk sharing agreements; relative effectiveness

Indexed keywords

ARTICLE; DELPHI STUDY; DRUG APPROVAL; DRUG EFFICACY; EUROPE; FUNDING; HEALTH CARE CONCEPTS; HUMAN; LICENSING; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RELATIVE EFFECTIVENESS; SEMI STRUCTURED INTERVIEW; COMPARATIVE EFFECTIVENESS; DRUG DEVELOPMENT; INTERVIEW; PROCEDURES;

PRESCRIPTION DRUG;

COMPARATIVE EFFECTIVENESS RESEARCH; DELPHI TECHNIQUE; DRUG DISCOVERY; EUROPE; HUMANS; INTERVIEWS AS TOPIC; PRESCRIPTION DRUGS;

EID: 84939428364     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.15.7     Document Type: Article

References (18)

1. High Level Pharmaceutical Forum. Final Conclusions and Recommendations of the High Level Pharmaceutical Forum. http://ec. europa. eu/enterprise/sectors/healthcare/files/docs
2. EUnetHTA. Joint Action 2, 2012-2015. www. eunethta. eu/activities/EUnetHTA%20Joint
3. European Medicines Agency. Road Map to 2015. www. ema. europa. eu/docs/en-GB/document-library
4. European Union. Commission Delegated Regulation (EU) No. 357/2014. Situations in which post-authorisation efficacy studies may be required. http://eur-lex. europa. eu/legal-content/EN/TXT/PDF/?uri
5. European Commission. Post-authorisation efficacy studies. Consultation document. http://ec. europa. eu/health/files/pharmacovigilance/2012
6. Boon WPC, Bouvy JC, Broekmans AW et al. Improving the EU system for the marketing authorisation of medicines. Learning from regulatory practice. http://escher. tipharma. com/fileadmin/media-archive/escher
7. European Medicines Agency. Adaptive licensing pilot project. www. ema. europa. eu/ema/index. jsp?curl=pages/regulation
8. Eichler H-G, Oye K, Baird LG et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91(3), 426-437 (2012).
9. Baird LG, Banken R, Eichler H-G et al. Accelerated access to innovative medicines for patients in need. Clin. Pharmacol. Ther. 96(5), 559-571 (2014).
10. Eichler H-G, Baird LG, Barker R et al. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin. Pharmacol. Ther. 97(3), 234-246 (2015).
11. Innovative Medicines Initiative. GETREAL: incorporating real-life clinical data into drug development. www. imi. europa. eu/content/getreal
12. Trusheim M. Better science, better health. New pathways and new sources of evidence, what do we need? http://vitaltransformation. com/wp-content/uploads
13. Towse A. New challenges for improving european health care: earlier access to innovation-is it worth it? Presented at: ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, 8-12 November 2014.
14. Baird LG, Trusheim MR, Eichler H-G et al. Comparison of stakeholder metrics for traditional and adaptive development and licensing approaches to drug development. Ther. Innov. Regulat. Sci. 47(4), 474-483 (2013).
15. Messner D, Mohr P, Towse A. Futurescapes: evidence expectations in the US for CER for drugs in 2020. J. Comp. Eff. Res. doi:10. 2217/CER. 15. 6 (2015) (Epub ahead of print).
16. Messner D, Towse A, Mohr P, Garau M. The future of evidence generation for comparative effectiveness and relative efficacy of drugs, an international perspective. J. Comp. Eff. Res. doi:10. 2217/CER. 15. 8 (2015) (Epub ahead of print).
17. EunetHTA. The final version of HTA Core Model and the Methodological Guidelines for Rapid REA of Pharmaceuticals. www. eunethta. eu/news/final-version-hta-core-model-and
18. Garrison, LP Jr, Towse A, Briggs A et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: ISPOR good practices for performance-based risk-sharing arrangements task force report. Value Health 16, 703-719 (2013).